I received a telephone call recently from a man who was angry and upset. All he could say was, but I’m not dying, I’m not dying! I was finally able to calm him down enough to be able to get him to tell me his story. It seems that his doctor told him that it [...]
Obesity has been associated with a worse prostate cancer prognosis and increased levels of insulin are thought to mediate this effect. It has been established that hyperinsulinemia associates with higher levels of insulin receptors (IR) in prostate cancers and increased tumor growth. Men with prostate cancer who are put on androgen blockade (ADT) develop increased [...]
As of today there are many different potential drugs undergoing phase III evaluations for men with advanced prostate cancer, some of them seem to offer great hope and promise. Considering we just had Provenge finally approved, this is great news. […]
A phase III study released at the ASCO meeting demonstrated that for men with bone metastases from prostate cancer, denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. […]
We have talked about it many times in past posts, the potential that many believe combination therapy can hold for better treatments for all cancers, including advanced prostate cancer. Combination therapy has made AIDS treatment as successful as it has become and it holds a similar promise for cancer treatment. An example of this potential [...]
It is truly amazing and very shocking, from 1996 to 1999, the U.S. food and Drug Administration (FDA) approved 157 new drugs. Compared to the period of 2006 to 2009 the FDA approved 74 drugs. However, NOT one of these approved drugs provided a cure for any serious illness! Diseases that destroy lives, diseases like [...]
In 2007 a Norwegian cancer therapeutics company, Algeta, presented data from a phase II study that showed a remarkable two-year survival advantage with its investigational drug, Alpharadin (radium-223), when used as a as a treatment for castrate resistant prostate cancer (CRPC). […]
At the on-going AUA Meeting, Dr. Howard Scher along with a collaborating group of medical oncologists reported their data from a Phase I-II trial of MDV3100 in castration-resistant prostate cancer (CRPC). […]
The National Comprehensive Cancer Network (NCCN), a private organization which develops what has become the standard of care guidelines for clinical practice in oncology, has modified their guidelines to included sipuleucel-T (Provenge) as a part of its prostate cancer management guidelines. The guidelines specify Provenge as a category 1 treatment which is appropriate as salvage [...]
According to a study last year at Fox Chase Cancer Center, men whose prostate specific antigen (PSA) rise within 18 months of having primary radiotherapy are more likely to develop advanced prostate cancer and die of their disease. […]
